Amy Petty

Dr. Amy Petty

Second Year Resident

Start Year



What are your career interests?

Complex medical, general & procedural dermatology; translational dermatology research.


Why did you choose Duke for residency training?

I chose Duke for my residency training for many reasons. First, the collaborative and collegiate environment created by faculty, staff and residents is the optimal for learning in residency. Secondly, the diverse patient population seen in various clinics at Duke and the VA provide a comprehensive understanding of dermatologic conditions in different demographics. Lastly, the vast basic science, translation and clinical research opportunities allow me to explore areas of dermatologic research to which I hope to contribute in the future.


Education & Training

Undergraduate:  Winthrop University, Bachelor of Science double majoring in Chemistry & Biology, 2012.

Medical School: Duke University School of Medicine, M.D. 2021.

Graduate School: Duke University Graduate School, Molecular Cancer Biology, Ph.D., 2021.

Internship: Internal Medicine, University of North Carolina Hospitals, 2021-2022.

Residency: Dermatology, Duke University, 2022-2025.


Awards & Honors

  • NIH Ruth L. Kirschstein National Research Service Award Individual Pre-Doctoral MD/PhD Fellowship/F30 Grant from NCI (2017-2021)
  • US Patent – “Compositions and methods to increase CD8+ T cell infiltration and function for the treatment of cancer” (2020)
  • Duke Graduate School Fitzgerald Academic Achievement Award (2017-2018)
  • Duke Graduate Student Travel Award (2018 & 2020)
  • Duke Cancer Institute 4th Annual Symposium Outstanding Research Award (2016)
  • Tillman Award/Valedictorian Award (May 2012)
  • American Chemical Society Outstanding Scholastic Achievement Award (2011)
  • American Society for Biochemistry and Molecular Biology National Honor Society Inductee (2011)
  • Phi Beta Kappa National Honor Society Inductee (2011)


Publications & Presentations

  • Jiang, S.W.; Petty, A.J.; Nicholas, M.W. Innate immunity in calcinosis cutis. Immuno 2022, 2(3), 443-459.
  • Jiang, S.W.; Kwock, J.T.; Liu, B.; Petty, A.J.; et al. High-dose, high-frequency ustekinumab therapy for patients with severe hidradenitis suppurativa. British Journal of Dermatology 2022.
  • Petty, A.J.; Owen, D.H.; Yang, Y.; Huang, X. Targeting tumor-associated macrophages in cancer immunotherapy. Cancers 2021, 13 (21), 5318.
  • Petty, A.J.; Dai, R.; Lapalombella, R.; et al. Hedgehog-induced PD-L1 on tumor-associated macrophages is critical of suppression of tumor-infiltrating CD8+ T cell function. JCI Insight 2021, 6 (6): e146707
  • Atwater, A.R.; Petty, A.J.; Liu, B.; et al. Contact dermatitis associated with preservatives: retrospective analysis of North American Contact Dermatitis Group data, 1994 though 2016. JAAD 2021, 84 (4), 965-976.
  • Petty, A.J.; Cardones, A.R.; Marano, A.L. Analysis of clinical characteristics of drug-induced cutaneous lupus erythematosus in men. JAAD 2020, 83 (5), 1455-1457.
  • Petty, A.J. Whitley, M.J.; Balaban, A.; et al. Pyoderma gangrenosum induced by secukinumab in a patient with psoriasis successfully treated with ustekinumab. JAAD Case Reports 2020, 6 (8), 731.
  • Petty, A.J.; Floyd, L.; Henderson, C.; Nicholas, M.W. Cutaneous lupus erythematosus: progress and challenges. Current Allergy and Asthma Reports 2020, 20 (5), 1-10.
  • Petty, A.J.; Ackerson, B.; Garza, R.; et al. Meta-analysis of number needed to treat for diagnosis of melanoma by clinical setting. JAAD 2020, 82 (5), 1158-1165.
  • Petty, A.J.; Heyman, B.; Yang, Y. Chimeric antigen receptor cell therapy: overcoming obstacles to battle cancer. Cancers 2020, 12 (4), 842.
  • Lei, V.; Petty, A.J.; Atwater, A.R.; Wolfe, S.A.; MacLeod, A.S. Skin viral infections: host antiviral innate immunity and viral immune evasion. Frontiers in Immunology 2020, 11, 2791.
  • Petty, A.J.; Li, A.; Wang, X.; et al. Hedgehog signaling promotes tumo-associated macrophage polarization to suppress intratumoral CD8+ T cell recruitment. JCI 2020, 129 (12), 5151-5162.
  • Petty, A.J.; Yang, Y. Tumor-associated macrophages in hematologic malignancies; new insight and targeted therapies. Cells 2020, 8 (12), 1526.
  • Petty, A.J.; Yang, Y. Tumor-associated macrophages: implication in cancer immunotherapy. Immunotherapy 2017, 9 (3), 289-302.
  • Bush, B.M.; Brock, A.T.; Petty, A.J.; et al. The Wnt/b-catenin/T-cell factor 4 pathway up-regulates high-mobility group A1 expression in colon cancer. Cell Biochemistry and Function 2013, 31 (3), 228-236.
  • Presentation – “Pilot study evaluating the efficacy of crisaborole for morphea”; Rheumatologic Dermatology Society Annual Meeting, November 7th, 2020.
  • Poster – “Cutaneous lupus erythematosus in men: a review of 31 patients at Duke University Medical Center from 2007 to 2017”; Medical Dermatology Society Annual Meeting, March 19th, 2020.
  • Presentation – “Hedgehog signaling promotes polarization of tumor-associated macrophages to suppress intratumoral CD8+ T cell recruitment”; Translational Research Cancer Centers Consortium, March 4th-6th, 2020.
  • Poster - “Development of pyoderma gangrenosum during treatment of psoriasis with secukinumab”; Southeastern Consortium for Dermatology, October 4th-6th, 2019.
  • Presentation – “Hedgehog signaling induces polarization of tumor-associated macrophage polarization to suppress CD8+ T cells”; Keystone Symposia on Cancer Immunotherapy, March 10th, 2019.
  • Presentation - “A critical role of hedgehog signaling in inducing immunosuppressive functions of tumor-associated macrophages”; Keystone Symposia on Myeloid Cells, April 10th, 2018.
  • Presentation - “A critical role for hedgehog signaling in the polarization of Immunosuppressive tumor-associated macrophages”; Duke Cancer Institute 4th Annual Retreat, October 28th, 2016.


Dr. Petty has a weekly clinic in our resident continuity clinic at VA.  This clinic is run by both resident and attending physicians at VA.  To make an appointment with Dr. Petty, please call 919-416-8070.